 |
PSA is poor predictor of lethal prostate cancer
April 04, 2007The amount of prostate-specific antigen (PSA) in a man's bloodstream at the time of his prostate cancer diagnosis or its rate of change over the course of the disease does not adequately predict lethal prostate cancer, according to a study in the April 4 Journal of the National Cancer Institute.
Although men with untreated localized prostate cancer have high long-term survival rates, many patients undergo treatment anyway. In order to avoid unnecessary treatment, researchers want to identify methods to determine which patients will develop lethal prostate cancer. The rate of increase of PSA—a protein produced by the prostate—before prostate cancer treatment has been associated with the patient's prognosis, which suggests that early measurements of PSA may predict the behavior of the tumor.
To assess the accuracy of using PSA to predict prostate cancer outcome, Katja Fall, M.D., Ph.D., of the Karolinska Institute in Stockholm, and colleagues analyzed the rate of change of PSA levels in 267 men from Sweden, Finland, and Iceland who were diagnosed with early localized prostate cancer between 1989 and 1999. The researchers recorded the PSA levels for the first two years after diagnosis to capture the patients' early PSA patterns. The men in the study received no curative treatment for the first two years but were closely watched for signs of progression, which is called watchful waiting.
At the end of the follow-up in December 2003, 34 patients had died from prostate cancer, and 18 had developed metastatic prostate cancer but were still alive. Although initial PSA values and the rate of change were associated with later development of lethal prostate cancer, they were not accurate enough to predict lethal cancer.
"We conclude that PSA measurement is associated with prostate cancer prognosis and continues to be an important monitoring tool," the authors write. "However, early PSA characteristics perform poorly in distinguishing those who develop a lethal prostate cancer from those at low or no risk of disease progression. Therefore, better decision tools are needed for active monitoring of patients with early disease."
In an accompanying editorial, Dipen Parekh, M.D., of the University of Texas Health Science Center at San Antonio, and colleagues compared the results of this new study with their own work and found consistent results regarding PSA, as well as other measures that were related to prostate cancer risk. "These data demand that clinical trials commence now to examine surveillance strategies to help patients and their physicians identify and treat tumors that will otherwise be life threatening and to carefully follow those that will not. Our limited health care resources and the quality of life of an enormous number of men will benefit from this for decades to come," the authors write.
Journal of the National Cancer Institute
Related Prostate Cancer Current Events and Prostate Cancer News Articles
New medication treats drug-resistant prostate cancer in the laboratory
A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model.
Observation is safe, cost-saving in low-risk prostate cancer
Many men with low-risk, localized prostate cancers can safely choose active surveillance or "watchful waiting" instead of undergoing immediate treatment and have better quality of life while reducing health care costs, according to a study by researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital.
Biodegradable implant may lessen side effects of radiation to treat prostate cancer
Several years ago, Virginia Commonwealth University Massey Cancer Center became the first center in the United States to test an Israeli-invented device designed to increase the space between the prostate and the rectum in prostate cancer patients undergoing radiation therapy.
Molecular Imaging Enlists Prostate Enzyme To Detect Metastases
No matter where they have hidden, metastatic prostate cancer cells still express some of the same signaling as normal prostate cells; in some cases even more so, as with the PSMA enzyme. Harnessing this enzyme could mean the beginning of a new platform for prostate cancer detection, staging, treatment and post-treatment monitoring.
Hormonal treatment for endometrial cancer does not directly target the malignant cells
Progesterone, a female hormone that can be used as a therapy for endometrial cancer, eliminates tumor cells indirectly by binding to its receptor in stromal or connective tissue cells residing in the tumor microenvironment, according to a study from the G.O. Discovery Lab team and collaborators at UCLA.
Clinical Sequencing Technology Identifies New Targets in Diverse Cancers
Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
New method to sensitize human ovarian cancer cells to a targeted cytotoxic drug
A novel, targeted approach to chemotherapy that makes ovarian cancer cells more susceptible to the cytotoxic effects of an antitumor drug may offer a safer, more effective treatment option for this often deadly form of cancer.
Researchers identify novel class of drugs for prostate cancers
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.
New diagnostic technology may lead to individualized treatments for prostate cancer
A research team jointly led by scientists from Cedars-Sinai Medical Center and the University of California, Los Angeles, have enhanced a device they developed to identify and "grab" circulating tumor cells, or CTCs, that break away from cancers and enter the blood, often leading to the spread of cancer to other parts of the body.
African-Americans experience longer delays between diagnosis and treatment of prostate cancer
Among men with prostate cancer, African Americans experience longer treatment delays after being diagnosed than Caucasians. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
More Prostate Cancer Current Events and Prostate Cancer News Articles
 |
Dr. Patrick Walsh's Guide to Surviving Prostate Cancer by Patrick C. Walsh (Author), Janet Farrar Worthington (Author) Each year, more than 230,000 men are diagnosed with prostate cancer, and 30 to 40 percent of patients who are diagnosed will eventually relapse. But the good news is that more men are being cured of this disease than ever before. Now in a revised third edition, this lifesaving guide by Dr. Patrick Walsh and award-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is a different disease in every man, which means that the right treatment varies for each man. Readers will discover their risk factors, simple changes that can reduce the risk of developing the disease, treatment options, and more. This new edition is updated to maintain its cutting edge as the world's most popular and well-respected resource on... |
 |
Prostate Cancer Breakthroughs: New Tests, New Treatments, Better Options -- A Step-by-Step Guide to Cutting Edge Diagnostic Tests and 8 Medically-Proven Treatments by Jay S. Cohen (Author) Prostate Cancer Breakthroughs by Jay S. Cohen, M.D. is the first and only book that focuses on the new tests and treatments that are beginning to revolutionize the care of men with prostate cancer. Today, tens of thousands of men diagnosed with prostate cancer get surgery or radiation they don't need with their serious and permanent side effects. Many doctors are not aware of the new tests and treatments that are available, so they do not relay this new information to their patients. In a step-by-step manner, Prostate Cancer Breakthroughs informs men of the new methods and how and where to obtain them. In this highly-praised book, you'll discover: -- Why a high PSA test does not necessarily mean cancer. -- Why you should continue to get annual PSA testing. -- New... |
 |
You Can Beat Prostate Cancer: And You Don't Need Surgery to Do It by Robert J. Marckini (Author) The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an internatio |
 |
The Definitive Guide to Prostate Cancer: Everything You Need to Know about Conventional and Integrative Therapies by Aaron Katz (Author) The complete guide to coping with prostate cancer, with expert health advice for every man This comprehensive handbook gives men the vital information they need to effectively navigate every step of dealing with prostate cancer. A newly diagnosed cancer patient faces a mind-numbing array of treatment options, including medical therapies that carry serious side effects—and determining the right course of action is an overwhelming task. In simple yet scientific terms, this book empowers readers with the tools they need to proactively fight cancer by making the most informed treatment decisions possible. With groundbreaking developments recently emerging in both conventional and holistic prostate cancer research, it is imperative that men fighting this disease have the absolute... |
 |
The Decision: Your prostate biopsy shows cancer. Now what?: Medical insight, personal stories, and humor by a urologist who has been where you are now. by John C. McHugh M.D. (Author), Johanna C. Craig Ph.D. (Editor), Graham L. Gaines (Editor), William P. Black (Editor), Travis Massey (Editor), Sandra B. Brim Ph.D. (Editor), Janice K. Watts (Editor) Over 200,000 times a year in the U.S. a patient will leave his urologist's office having been told he has prostate cancer. What the patient thought to be a disease of old men from which they do not die, now becomes a very complicated and frustrating dilemma about which treatment to pursue. "The Decision" offers the reader an insider's view to the key issues necessary for a well thought-out treatment plan peculiar only to him. Being a urologist who treats prostate cancer and having had the disease as well, uniquely positions the author in offering guidance to the newly diagnosed prostate cancer patient. Dr. McHugh outlines a novel and multifaceted approach, using an eclectic mix of medical insight ,personal stories and humor, to aid the reader in making his "Decision." The US Review of... |
 |
Prostate and Cancer: A Family Guide to Diagnosis, Treatment, and Survival by Sheldon Marks MD (Author) Prostate cancer is one of the most common cancers affecting American men, with over 186,000 new cases diagnosed in the United States annually; 1 in 6 men will be diagnosed with prostate cancer during his lifetime. Renowned prostate cancer specialist Sheldon Marks offers the definitive guide for men concerned about or diagnosed with prostate cancer, and for their families.Since the third edition (2003), there have been significant changes in treatment and resources. Working with Dr. Judd Moul, the Chairman of Urology at Duke and one of the world’s top experts on prostate cancer, Marks provides the most up-to- date information on diagnosis, treatment, and common questions. |
 |
Winning the Battle Against Prostate Cancer by Gerald Chodak MD (Author) Prostate cancer is the second most common cancer in men with almost 200,000 new cases being diagnosed each year. Today increasing numbers of men and their families play a more active role in their treatment and the results can be seen in the increase of men who survive prostate cancer. Yet each year over 27,000 men die from prostate cancer. This makes prostate cancer the second leading cause of cancer death in men behind lung cancer. The range of controversial therapies and treatments for prostate cancer is greater than that of any other cancer affecting men. This makes it difficult for men and their families to determine what are the best options available. Rarely do doctors agree on which treatment a patient should receive or when they should receive it. And many of the current books on... |
 |
Prostate Cancer. Essential Concepts for Survival by Stephen B. Strum, MD The Goal Prostate Cancer Essential Concepts for Survival distills 30 years of the author's experience as a medical oncologist specializing in prostate cancer while working with thousands of men with this disease. Within "Essential Concepts", eight crucial concepts linked to optimal outcome are presented and illustrated. The reader is able to discuss these with his medical team and incorporate them into a refined strategy to beat this disease. The Contents Within this eBook are 32 color graphics, 7 tables, over 150 peer-reviewed citations, a comprehensive medical glossary and links to valuable resources. Warning to Readers! This book contains crucial concepts in the evaluation and management of prostate cancer that are commonly ignored by many... |
 |
Prostate Cancer For Dummies by Paul H. Lange (Author), Christine Adamec (Author) Hearing that you have prostate cancer, or even that you may have it, is very scary. But this disease, in many cases, is curable. Even if you have advanced cancer that's spread beyond the prostate, many treatments help extend your life for years. You need good information to help you with the decisions that lie ahead, and this book provides you with this information.Prostate Cancer For Dummies can help you ifYou have prostate cancer (or you think that you have it), or someone close to you has it.You want information on treatments for prostate cancer as you form a treatment plan with your doctor.You are curious about alternative therapies for prostate cancer.You want to know what actions you can take over the long-term to continue to fight your prostate cancer.Prostate Cancer For Dummies... |
 |
After Prostate Cancer: A What-Comes-Next Guide to a Safe and Informed Recovery by Arnold Melman M.D. (Author), Rosemary Newnham (Author) Men who have completed prostate cancer treatment often find themselves facing new challenges and setbacks that do not necessarily recede along with the cancer. Many books endeavor to explain the different types of prostate cancer treatments, but most conclude once a treatment choice has been made, offering readers little in the way of guidance through the challenges of the post-treatment period. After Prostate Cancer: A What-Comes-Next Guide to a Safe and Informed Recovery picks up where those books leave off. Dr. Arnold Melman, Chair of the Department of Urology at the Albert Einstein College of Medicine, offers a thorough description of what the prostate cancer recovery process is like and what readers can do to move themselves through recovery to the best possible health and... |
| © 2013 BrightSurf.com |